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Cellular energy is a cornerstone of metabolism and is crucial for human health and disease. 27 
Knowledge of the cellular energy states and the underlying regulatory mechanisms is 28 
therefore key to understanding cell physiology and to design therapeutic interventions. 29 
Cellular energy states are characterised by concentration ratios of adenylates, in particular 30 
ATP:ADP and ATP:AMP. We applied synthetic biology approaches to design, engineer and 31 
validate a genetically encoded nano-sensor for cellular energy state, AMPfret. It employs the 32 
naturally evolved energy sensing of eukaryotic cells provided by the AMP-activated protein 33 
kinase (AMPK). Our synthetic nano-sensor relies on fluorescence resonance energy transfer 34 
(FRET) to detect changes in ATP:ADP and ATP:AMP ratios both in vitro and in cells in 35 
vivo. Construction and iterative optimisation relied on ACEMBL, a parallelised DNA 36 
assembly and construct screening technology we developed, facilitated by a method we 37 
termed tandem recombineering (TR). Our approach allowed rapid testing of numerous 38 
permutations of the AMPfret sensor to identify the most sensitive construct, which we 39 




One Sentence Summary: 44 
Rapid DNA assembly and parallelised construct screening tools enabled engineering of a 45 
potent FRET-based cellular energy sensor capable of detecting fluctuations in AMP 46 
concentrations and ADP/AMP ratios in vitro and in cells in vivo. 47 




Energy metabolism is key to cell survival and homeostasis. Metabolic and energy 50 
perturbations have been associated with a wide range of otherwise unrelated human 51 
diseases(1–5). A key sensor and regulator of cellular energy metabolism is adenosine 52 
monophosphate-activated protein kinase (AMPK), which is ubiquitously expressed and 53 
highly conserved throughout evolution(6–12). AMPK is a heterotrimeric serine/threonine 54 
kinase, comprising a catalytic subunit, α, and two regulatory subunits, β and γ. AMPK senses 55 
the variation in cellular adenylate levels, specifically the ratios of AMP to ATP, and ADP to 56 
ATP(13–15). It is activated in response to increases in the AMP:ATP and ADP:ATP ratios 57 
during periods of energetic stress, for instance exercise, caloric restriction or ischemia(10,16–58 
18). When the cellular concentration of AMP or ADP rises, these adenylates out-compete 59 
ATP for binding to the γ subunit and causes allosteric activation and a defined 60 
conformational change(19–21). The activated kinase then re-establishes a correct cellular 61 
energy state through the phosphorylation of downstream targets, causing inhibition of 62 
anabolic processes and activation of catabolic processes, thereby restoring the levels of ATP 63 
as a major energy source.  64 
AMPK has a central role in many metabolic processes and is implicated in many, 65 
otherwise unrelated diseases like cancer(22), neurodegenerative(5,23) and kidney 66 
diseases(24), rheumatism(25), and notably cardiovascular(26,27) and metabolic 67 
diseases(28,29). The kinase is increasingly recognised as a therapeutic target for many of 68 
these pathologies, and specific activators are being developed(30–32). Metabolic outcomes 69 
mediated by AMPK activation are particularly significant for diabetes mellitus(28,33). 70 
AMPK mediates some of the beneficial effects of metformin, the first-line medication for 71 
type 2 diabetes (T2D) (34), which activates the kinase indirectly via inhibition of 72 
mitochondrial respiratory Complex I and a rise in the ATP/AMP ratio (35,36). Similarly, 73 
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AMPK activation in muscle during and after exercise enhances muscle insulin sensitivity 74 
(37). In cancer, AMPK may be involved in both the induction and preventing tumours, 75 
depending on its metabolic state(22,38). Monitoring AMPK function and modulating cellular 76 
energetics by modifying AMPK regulation is thus considered as a key pharmaceutical 77 
concept for future therapeutic intervention.  78 
Currently, the predominating experimental methods commonly used to explore the 79 
activation state of AMPK are assays using cell and tissue extracts. This mostly includes 80 
immunoblotting with phospho-specific antibodies for AMPK or AMPK substrates, but also 81 
non-radioactive assays reporting phospho-incorporation into (artificial) substrates(39,40). 82 
These methods, however, only provide end-point data that average entire cell populations and 83 
that, as in the case of immunoblots, are only semi-quantitative. Immunofluorescence is also 84 
used, providing valuable insight into the localisation of the phosphoproteins in single cells. 85 
However, this method requires fixation for analysis, again preventing the analysis of living 86 
cells, and is not quantitative. Ideally, one would like to follow in time the AMPK activation 87 
at the single cell level in response to given stimuli, thus also assaying heterogeneity.  88 
An alternative method is the use of genetically encoded biosensors capable of 89 
measuring adenylate levels and ratios in single live cells, ideally by optical methods such as 90 
fluorescence resonance energy transfer (FRET). There are an increasing number of 91 
genetically encoded FRET biosensors emerging for a range of applications(41–46) including 92 
sensors that indirectly gauge AMPK function(47,48). For instance, AMPK Activity Reporter 93 
(AMPKAR) consists of a specifically designed, artificial peptide substrate of AMPK and a 94 
phosphothreonine-binding forkhead-associated domain 1 (FHA1), attached to a pair of 95 
fluorescent proteins capable of FRET(49). Upon AMPK activation, the artificial substrate is 96 
phosphorylated and binds to the FHA1 module, juxtaposing the donor and acceptor 97 
fluorophores resulting in a detectable FRET signal. AMPKAR and related sensors can also be 98 
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successfully targeted to different subcellular compartments(50) or entire animals(51). 99 
Nonetheless, these sensors are limited as they neither provide direct, immediate readout on 100 
AMPK activity, nor of adenylate ratios, which however are bona fide indicators of cellular 101 
energy states. Particularly, the available AMPK sensors report the full activation state of 102 
AMPK but do not distinguish between the energy-sensing modulation of AMPK 103 
phosphorylation by AMP and ADP and covalent activation via 104 
phosphorylation/dephosphorylation at the activation loop Thr172(7). They are neither truly 105 
reversible, since dephosphorylation of the artificial substrate must be catalysed by cellular 106 
phosphatases. A more detailed review of these AMPK substrate FRET sensors can be found 107 
in our recent review(47). 108 
To overcome the limitations of existing sensors, we therefore pursued a different 109 
approach. We sought to exploit the conformational change upon AMPK activation(19–21) to 110 
create a genetically encoded sensor based on AMPK itself, that could faithfully detect and 111 
monitor cellular energy states including the ratios between ATP:ADP and ATP:AMP. We 112 
reasoned that by attaching fluorophore pairs to the N- and C-termini of the AMPK subunits 113 
and testing all possible combinations, we could create a sensitive sensor that would produce a 114 
detectable FRET signal without perturbing cell metabolism. To create our AMPK-derived 115 
FRET sensor, AMPfret(52), we applied DNA assembly and construct screening methods that 116 
we had developed(52–55) facilitating our approach, and we applied protein engineering to 117 
optimise our sensor(52). The generation of the AMPfret sensor, and its validation in vitro and 118 







Main Text 124 
Constructing the AMPfret sensor 125 
Our AMPfret sensor is based on the native heterotrimeric AMPK itself, thus directly 126 
reporting on AMPK activation mechanisms as naturally evolved in eukaryotes(52). We 127 
utilised the α2β2γ1 isoform(56,57), outfitted with two fluorescent proteins at selected protein 128 
subunit termini to enable FRET. Upon increase in the cellular AMP:ATP ratio, AMPK 129 
undergoes allosteric activation, resulting in a pronounced conformational switch(19,20). In 130 
AMPfret, this causes the fluorescent proteins attached to the subunit termini to move in 131 
relation to each other, resulting in an increase in FRET. Thus, the FRET output signal 132 
detected is directly correlated to the conformational change that occurs on the functional core 133 
of the sensor during activation of AMPK.  134 
We required an appropriate expression system to facilitate the generation of the 135 
AMPfret sensor. Production of an array of constructs was required to identify which were the 136 
best termini to tag with the fluorescent proteins and each would need to be expressed, 137 
purified and characterised, first in vitro and ultimately within cellular systems in vivo. We 138 
had previously developed ACEMBL, a method for producing multiprotein complexes in E. 139 
coli(53). ACEMBL facilitates the rapid assembly of genes into multigene expression 140 
cassettes by combining sequence and ligation independent cloning methods (SLIC) and DNA 141 
recombination by a site specific recombinase, Cre, in a process we termed tandem 142 
recombineering (TR)(55). In TR, genes encoding for subunits of a multiprotein complex are 143 
inserted in custom designed minimalistic DNA modules called Acceptor and Donor plasmids, 144 
that contain bacterially active promoters (T7, lac), terminators, antibiotic resistance genes, the 145 
Cre recombinase recognition site, LoxP and a multiple insertion site (MIE) for inserting the 146 
genes of interest at specific restriction sites in a so-called multiplication module, to facilitate 147 
multigene assembly. Acceptors contain a regular origin of replication (BR322) that supports 148 
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survival in regular E. coli cells, while Donors contain a conditional origin of replication 149 
derived from the R6Kγ phage(58). Due to the conditional origin, Donors need to be 150 
propagated in special E. coli cells that express the pir gene – for survival in regular E. coli 151 
cells. In contrast, Donors need to be fused with an Acceptor by Cre-LoxP mediated plasmid 152 
fusion for survival in regular strains(54). We cloned each of the three subunits of AMPK in 153 
an Acceptor or Donor plasmid, respectively, and tagged each of the six termini (N-terminus, 154 
C-terminus) with a fluorescent protein pair capable of FRET, to identify the combination that 155 
yielded the highest signal depending on adenylate concentrations (Fig. 1).  156 
We first chose enhanced cyan fluorescent protein (eCFP) and yellow fluorescent 157 
protein (YFP) for our experiments as eCFP and YFP constitute a potent FRET pair. In order 158 
to identify the most appropriate positions for robust FRET upon activation, all possible 159 
permutations were generated (Fig. 1). This involved inserting each AMPK subunit into a 160 
separate plasmid, with or without the addition of the fluorescent proteins at either the N- or 161 
C-terminus (Fig. 1). Expression and purification of the resulting sensor variants allowed us to 162 
identify the most sensitive biosensor, that maximally exploited the conformational changes 163 
that are associated with the allosteric activation of AMPK in vitro (Fig. 1B,C). More 164 
precisely, the α2 subunit, with or without the donor fluorescent protein, eCFP, at the N- or C-165 
terminus was cloned into the acceptor plasmid, pACE1. To facilitate purification, a DNA 166 
encoding for a decahistidine tag and a tobacco etch virus (TEV) protease cleavage site was 167 
also inserted at the N-terminus of the construct. The β2 subunit, likewise with or without the 168 
acceptor fluorescent protein, YFP, at the N- or C-terminus was cloned into a donor plasmid, 169 
pDC. Finally, the γ1 subunit was inserted into the donor plasmid pDS (Fig. 1). This final γ1 170 
subunit was either untagged, or again combined with all possible combinations of the 171 
fluorescent proteins at either the N- or C- terminus. The resulting constructs were then fused 172 
by their respective LoxP sequences by Cre recombinase (Fig. 1B) to form all possible 173 
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variations (AMPfret constructs A to L) of the putative AMPfret sensor (Fig 1D). Restriction 174 
mapping of the plasmids, predicted by a software we developed, Cre-ACEMBLER(54), 175 
helped to confirm the identity of the fusion plasmids, which were then further confirmed by 176 
sequencing. The sensors were then expressed in E. coli and purified to homogeneity using 177 
immobilised metal affinity (IMAC) using the decahistidine tag, ion exchange 178 
chromatography (IEX) and size exclusion chromatography (SEC)(52). All constructs were 179 
tested for variation in FRET upon activation with AMP in vitro, and a construct comprising 180 
an α subunit tagged with eCFP at the C-terminus, a β subunit tagged with YFP at the C-181 
terminus, and a γ subunit that remained untagged was revealed as the best candidate(52). Of 182 
note, these sensors were quite insensitive to pH changes and did not respond to guanylates 183 
(GMP), as it is the case for AMPK(52).  184 
Optimising AMPfret 185 
We next sought to improve the dynamic range of our sensor by increasing the signal 186 
window of the FRET signal produced (Fig. 1C). A range of fluorescent protein pairs capable 187 
of FRET exists, each with its own merits, and they are constantly being improved for various 188 
characteristics, including quantum yield(46,59). Thus, the eCFP and YFP pair was replaced 189 
by the more efficient FRET pair: mseCFP and mVenus.cp173, in order to obtain a sensor 190 
more resistant to salt and pH changes(52,60,61). We had designed our original AMPfret 191 
constructs such that we could now carry out exchange of fluorophores by traditional 192 
restriction digestion and ligation methods by exploiting restriction sites that flanked the 193 
fluorescent proteins. Next, we contemplated the flexibility of the fluorophores within the 194 
sensor’s structure. Secondary structure predictions (nps@consensus, ClustalW2 and psipred 195 
servers) conveyed the presence of unstructured amino acid residues at the termini of the 196 
AMPK subunits. FRET is highly susceptible to the geometry of the fluorophores with respect 197 
to each other. We therefore reasoned that restricting the flexibility of the fluorescent proteins 198 
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by removing these disordered residues located at the AMPK subunit termini may be 199 
beneficial by reducing the random plasticity in the sensor. We inspected a crystal structure of 200 
AMPK (PDBID 2Y94) to define ordered boundaries of the AMPK subunits. Based on this 201 
analysis and the secondary structure prediction outputs, we removed two residues (AR) from 202 
the C-terminus of the α subunit, three residues (KPI) from the C-terminus of the β subunit 203 
and eight residues (LTGGEKKP) from the C-terminus of the γ subunit. This resulted in the α 204 
and γ subunits terminating in precisely folded α-helical structures, and the β subunit 205 
terminating in a defined β-strand motif. Concomitantly, we also removed the restriction sites 206 
we had introduced in our original AMPfret constructs that were used for screening, 207 
eliminating two further amino acid residues. These modifications were carried out by PCR-208 
based SLIC procedures(55).  209 
Finally, a further modification was carried out through the addition of a linker 210 
sequence forming a particularly rigid α helix, comprising tandem repeats of negatively and 211 
positively charged ER/K amino acids(62). We inserted this rigid α helix in between the α 212 
subunit and the respective fluorophore attached to it. A corresponding eight amino acid α-213 
helical linker was introduced to quasi ‘lock’ the fluorophore in place with respect to the 214 
AMPK subunits. Thereby, maximally translating the conformational change upon AMPK 215 
activation into a FRET signal by restricting the freedom of movement of the donor 216 
fluorescent protein with respect to the AMPK complex core and the acceptor fluorophore 217 
(Fig. 2A).  218 
The combination of these measures proved to be beneficial and resulted in a 219 
significantly improved second-generation AMPfret sensor. The FRET signal difference upon 220 
activation substantially increased from approximately 7% to 20%, providing an efficient and 221 
reliable genetically encoded biosensor of AMPK activity in vitro (Fig. 2B,C)(52). 222 
  223 
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Deploying the AMPfret sensor in vivo in cellular systems 224 
Our ultimate goal was to create a sensitive biosensor that could be applied within 225 
cellular systems to provide a faithful optical readout for cellular energetics. Therefore, we 226 
investigated the potential of our optimised AMPfret sensor in cells. For this, new constructs 227 
were required utilising mammalian active promoters. Our ACEMBL system comprises not 228 
only prokaryotic expression reagents, but also plasmids in an identical format that can be 229 
used for eukaryotic expression in either insect or mammalian cells. We grafted the genes 230 
encoding for our optimised second generation AMPfret biosensor into the mammalian active 231 
equivalent plasmids of the ACEMBL suite, MultiMam(63), and applied TR to generate the 232 
multigene AMPfret construct for expression of our sensor within mammalian cells. A range 233 
of mammalian cell lines including HEK293T, HeLa and 3T3-L1 were transfected and the in 234 
cellulo activation of AMP was investigated by the addition of known activators of AMPK, 235 
AICAR and 2-DG, compellingly validating our approach and the utility of our sensor in cells 236 
in vivo (Fig. 2D,E). Our experiments yielded important new insight into adenylate-dependent 237 
AMPK activation mechanisms(52). 238 
 239 
Summary and outlook 240 
By utilising DNA assembly and construct screening technologies we had developed, we 241 
created, to the best of our knowledge, the first bona fide sensor of cellular energy states. In 242 
our experiments, AMPfret proved capable of sensing AMP levels and adenylate ratios, 243 
resulting in changes in the detectable FRET signal from the fluorophores attached to AMPK 244 
subunit termini, that we engineered for optimal signal intensity. We provided evidence that 245 
AMPfret can be used as a robust and effective sensor, for both in vitro and in cells in vivo 246 
applications. The use of this sensor in cells generates many exciting opportunities for future 247 
applications. Being able to assess the activation of AMPK within its native environment may 248 
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unlock intricate signalling pathways that this kinase is involved in. Moreover, our results 249 
firmly set the stage for identifying modulators of AMPK function including small molecule 250 
compounds of potential therapeutic benefit in the future. Finally, AMPfret holds the promise 251 
of providing a generic probe at the single cell level to analyse adenylate ratios that govern 252 
cellular activity in health and disease. 253 
We see ample further scope for optimising AMPfret. The fact that AMPfret consists 254 
of three polypeptide chains, which also recombine with cell-endogenous AMPK subunits, 255 
does not lead to a detectable decrease in sensitivity. Thus, a primary goal would be to create 256 
new versions of the sensor that could be even more sensitive and robust, as well as tailored 257 
for specific applications. For example, there is now a wide variety of well characterised 258 
fluorescent proteins covering the entire range of the electromagnetic spectrum, from the ultra-259 
violet excitation blue colours, to the infra-red emitting red colours, many of which can be 260 
used together as FRET pairs(41,42,59). Such sensors may avoid disturbing endogenous 261 
fluorescence due to NADH or other fluorophores in specific cell types. An enhanced FRET 262 
signal was already observed when exchanging the FRET pair in both AMPfret variants, 263 
however thus far, only blue-yellow FRET pairs have been explored(52). New and emerging 264 
FRET biosensors appear to favour more red-shifted FRET pairs, exploiting the potentially 265 
larger Forester radii (R0s) obtained with longer wavelengths(42,64), which may result in a 266 
further enhanced FRET efficiency and therefore, an increase in sensitivity. For cellular 267 
applications, a further red-shifted donor fluorophore also has the possible advantage that a 268 
larger wavelength is used to excite the fluorophore as compared to CFP and its derivatives, 269 
utilising a lower energy. This can be beneficial to reduce autofluorescence and phototoxicity 270 
of the cells analysed.  271 
Further strategies may include utilising alternative isoforms of the AMPK subunits 272 
that may be more suited to specific cell types and may have varying regulation 273 
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mechanisms(65,66). Alternative linker strategies could also be considered, with rigid α-274 
helical linkers in between the β subunit and the acceptor fluorophore. This may stabilise a 275 
configuration of the fluorophores with increased FRET efficiency upon activation. Another 276 
option could be to vary the length of the linkers utilised, to adjust the distance and pitch 277 
between the fluorophores in the sensor. In general, iterative rounds of optimisation by 278 
permutating fluorophore placement and orientation may be pursued when new fluorescent 279 
proteins are inserted into the sensor, to ensure the maximum possible efficiency is obtained.  280 
AMPfret provides a largely homogeneous readout for the cytosolic space, and a 281 
weaker signal for the nucleus. Further subcellular localizations identified as crucial for 282 
AMPK glucose sensing via fructose-1,6-biphosphate, namely lysosome and 283 
mitochondria(67,68), are not visualized so far. Likely, the pool of AMPK (or AMPfret) 284 
associated there is limited. Thus, targeted sensors are needed, which are easily 285 
conceivable(50) by supplying organelle and cell compartment specific tags. Similarly, cell 286 
type specific promoters can provide AMPfret expression in a specific subset of cells in a 287 
tissue.  288 
All these and further modifications are greatly facilitated by the modular nature of the 289 
ACEMBL system utilised here for iterative sensor construction (Fig. 1A-C). With the 290 
subunits present in separate plasmids, their manipulation is straight forward, as is the 291 
regeneration of the complete, sensor encoding construct by Cre recombinase mediated 292 
plasmid fusion. We anticipate an entire tool-kit of AMPfret-derived sensors, each with 293 
customised properties, ready to probe energy states and uncover functional mechanisms in a 294 







• Cellular energy states are key indicators of cell function, in health and disease.  300 
• Based on the metabolic hub AMPK, we developed our genetically encoded synthetic 301 
sensor, AMPfret, to monitor energy states by faithfully measuring adenylate ratios in vitro 302 
and in cells in vivo.  303 
• Biochemical and biophysical characterisation of AMPfret revealed novel mechanisms of 304 
AMPK activation.   305 
• Based on our results, we envisage a tool-kit of tailored AMPfret biosensors with diverse 306 
properties, for a multitude of applications, including screening for small molecule 307 
compounds for future therapeutic interventions by targeting cell energetics. 308 
  309 
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Figures and Legends 499 
 500 
Figure 1. Constructing biosensor AMPfret. (A) AMPfret was expressed in E. coli and 501 
purified. The α subunit of AMPK and a fluorescent protein (YFP) were cloned into pACE1, a 502 
so-called Acceptor plasmid module from the ACEMBL suite(52,53). The β subunit of AMPK 503 
and a second fluorescent protein (CFP) was cloned into pDC, and the γ subunit of AMPK was 504 
cloned into pDS, respectively. pDS and pDC are so-called Donor plasmids in the ACEMBL 505 
suite(52,53). The Cre recombinase recognition site, LoxP, is shown as a red circle; the T7 506 
prokaryotic promoter as a black triangle; the genes encoding for antibiotic resistance in 507 
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coloured rectangles. Origins of replication, BR322 and R6Kγ, are displayed as black and grey 508 
boxes, respectively. CFP, cyan fluorescent protein; YFP, yellow fluorescent protein; Ap, 509 
ampicillin; Cm, chloramphenicol; Sp, spectinomycin; ori, origin of replication. (B). 510 
Multigene expression constructs are prepared from Donor and Acceptor plasmids by Cre-511 
LoxP plasmid fusion mediated by the Cre recombinase. Acceptor-donor fusions (AD) and the 512 
acceptor-donor-donor (ADD) fusion are identified by the resistance marker combinations.  513 
ADD fusion pAMPfret comprises the genes encoding for the heterotrimeric sensor including 514 
the functional FRET pair. (C). ACEMBL high throughput pipeline utilised for the generation 515 
of AMPfret sensors. The desired genes encoding for the AMPK subunits and fluorescent 516 
proteins were inserted into the respective acceptor and donor plasmid backbones by SLIC and 517 
combined Cre-LoxP fusion. This process is termed tandem recombineering (TR). Fusion 518 
constructs are then screened by fusion plasmid restriction mapping, facilitated by the Cre-519 
ACEMBLER software, and correct clones confirmed by DNA sequencing. AMPfret variants 520 
are expressed and purified and followed by in vitro characterisation analysing changes in 521 
FRET signal upon activation. This process is iteratively repeated and the sensor optimised 522 
whereby components such as the fluorescent proteins and linker regions are modified. (D). 523 
Schematic depicting the topology of AMPfret variants initially constructed for testing. CFP 524 
and YFP are represented as blue and yellow ovals respectively. AMPK subunits, α, β and γ 525 
are shown as labelled grey rectangles. 526 




Figure 2. Characterisation of AMPfret in vitro and in cells in vivo. (A) The optimized 529 
AMPfret biosensor is shown in a cartoon representation illustrating the mode of action upon 530 
sensor activation. The structure shown is based on heterotrimeric AMPK with subunits α, β 531 
and γ coloured blue, orange and magenta, respectively. The fluorescent protein mseCFP is 532 
shown as a blue circle, a small rigid α-helical linker is coloured in red and the fluorescent 533 
protein cp173-mVenus is shown as a yellow circle. A conformational change occurs 534 
following the binding of AMP or ADP to the γ subunit, resulting in FRET signal change. 535 
Excitation and emission wavelengths are shown for each fluorophore. The model was based 536 
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on AMPK crystal structures (PDB ID 4EAK, 4EAI and 5ISO), bound AMP is drawn in a 537 
space filling representation. (B) In vitro characterisation of AMPfret showing a positive 538 
change in FRET upon activation with AMP. Bars coloured in grey depict AMPfret subunits. 539 
The rigid linker helix is shown as a red box. Normalised fluorescence spectra of untreated 540 
(blue) and activated (orange) AMPfret are shown. (C) Normalised FRET ratio calculated 541 
from the curves in panel B, using the same colour code. The AMPfret encoding multigene 542 
expression plasmid was transfected into HEK293T (D) and 3T3-L1 (E) cells and the FRET 543 
signal measured over time upon addition of AICAR (1 mM) or 2- deoxy glucose (2-DG, 20 544 
mM). Micrographs of cells imaged in the CFP and YFP channels are shown (scale bars: 50 545 
µm). Adapted from (52). 546 
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